FDA Commissioner Marty Makary Continues Duties Amid Reports of Potential Dismissal

2026-05-12

The BareStory

FDA Commissioner Marty Makary remains in his position and is continuing his official duties, despite reports that President Trump has approved a plan for his dismissal. White House spokesperson Kush Desai characterized the reports of an impending firing as media distractions, while a person familiar with the matter stated that Makary has not been directly asked for his resignation.

The uncertainty surrounding Makary’s employment status follows internal disputes over the agency's regulatory agenda. Earlier this month, the FDA authorized flavored e-cigarettes after Trump applied pressure on Makary to approve the products, a directive the commissioner had previously resisted. Administration advisers reportedly told the president that Makary was obstructing the administration's vaping agenda and described him as a problem.

When asked about the potential firing on Friday, Trump stated he had read about the situation but lacked direct knowledge. While Makary was absent from an Oval Office meeting on maternal health with other federal health officials on Monday, he continued his agency duties and was featured in an official FDA press release regarding drug repurposing the same day.

According to a spokesperson for the Senate Appropriations Committee, Makary remains scheduled to testify before the legislative panel on Wednesday regarding the administration’s budget proposal. Makary, a British-American surgeon confirmed to the post in March 2025, has faced recent criticism from former FDA Commissioner Scott Gottlieb, who claimed on Monday that Makary’s tenure has been characterized by missteps and ineffective leadership. Meanwhile, a senior health department official claimed the commissioner maintains substantial support among staff inside the agency.

Left Perspective

Shielding Public Health Mandates
Defending Bureaucratic Independence
Chilling Effect on Regulators

Right Perspective

Executing the Electoral Mandate
Restoring Cohesive Administrative Order
Erosion of Executive Authority

Left Perspective

• Shielding Public Health Mandates Government accountability relies on regulatory agencies prioritizing the vulnerable over political whims or corporate interests. The revelation that Trump successfully pressured Makary to authorize flavored e-cigarettes represents a critical failure of institutional firewalls. For reformers, overriding a commissioner’s resistance to force through a controversial, industry-friendly vaping agenda dangerously subordinates scientific consensus to executive demands.

• Defending Bureaucratic Independence Maintaining agency autonomy is vital for challenging systemic corruption and preserving civil liberties. Makary’s choice to proceed with FDA press releases on drug repurposing and maintain his scheduled Senate budget testimony—despite being excluded from an Oval Office meeting—is viewed as a successful assertion of independence. The substantial support he retains among agency staff validates the necessity of career civil servants holding the line against politically motivated coercion.

• Chilling Effect on Regulators The long-term fear is the total erosion of the FDA's objective credibility. If a Senate-confirmed commissioner is dismissed merely for obstructing an administration's specific political agenda, it signals to all federal health officials that compliance is mandatory for survival. This normalizes an environment where agency heads become political rubber stamps, stripping the public of crucial protections against unchecked executive overreach.

Right Perspective

• Executing the Electoral Mandate Institutional continuity demands a unified executive branch where appointed officials reliably execute the elected president's priorities. Reports that Makary was actively obstructing the administration’s vaping agenda frame the commissioner’s resistance not as heroism, but as a failure of the chain of command. Traditionalists view the role of an agency head as an implementer of the administration’s broader strategy, making insubordination a threat to the constitutional mandate of the presidency.

• Restoring Cohesive Administrative Order Effective governance requires systemic stability and aligned leadership. Former FDA Commissioner Scott Gottlieb’s public criticism of Makary’s tenure as "ineffective" highlights a breakdown in functional administration. Makary's conspicuous absence from the Oval Office maternal health meeting illustrates a paralyzed relationship; for traditionalists, allowing an agency to operate in isolated defiance of the White House undermines the basic rule of law and organizational discipline.

• Erosion of Executive Authority The overarching risk is the institutional weakness projected by ongoing, unresolved internal disputes. While the White House characterized the firing reports as media distractions, sending a politically isolated commissioner to testify before the Senate Appropriations Committee projects administrative disarray. Failing to decisively resolve Makary's employment status allows the federal bureaucracy to calcify, weakening the executive branch's ability to drive its statutory and regulatory agenda.

How it may affect me

As a U.S. reader:

• In the short term, consumers now have authorized access to flavored e-cigarettes due to the administration successfully pushing its vaping agenda through the FDA.

• Over the long term, the nature of federal health protections may shift if agency credibility is eroded and independent scientific consensus is increasingly bypassed in favor of executive directives.

• Ongoing friction between the White House and the FDA could cause administrative disarray, potentially complicating or delaying the execution of a unified, national regulatory health policy.

• Despite the leadership uncertainty, immediate FDA operations that impact public healthcare, such as drug repurposing programs and federal budget planning, are continuing to function.

FDA Commissioner Marty Makary Continues Duties Amid Reports of Potential Dismissal

The BareStory

Left Perspective

Right Perspective

How it may affect me

Read the story at